Company: NAVN
Filing Date: 2025-07-28
Form Type: DRS/A
Source: 0001628279-25-000476
Chunk: 361

Company: Navan, Inc.
Filing Date: 2025-07-28
Form: DRS/A
Chunk 361
---
 the indemnification set forth in its amended and restated certificate of incorporation and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought. The indemnification provisions in its amended and restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the directors and executive officers for liabilities arising under the Securities Act.

The Registrant currently carries liability insurance for its directors and officers.

Certain of the Registrant’s directors are also indemnified by their employers with regard to service on the Registrant’s board of directors.

In addition, the underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification by the underwriters of the Registrant and its officers and directors for certain liabilities arising under the Securities Act, or otherwise.

## ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES.
Since February 1, 2022, the Registrant has issued and sold the following securities:

• In April 2025, the Registrant issued SAFEs to accredited investors in an aggregate principal amount of $53.8 million.

• In April 2025, the Registrant issued warrants to purchase up to approximately 0.16% of the Registrant’s capital stock on a fully diluted basis, calculated as of the initial public filing of this registration statement, to accredited investors at an exercise price of $0.01 per share.

• In February 2025, the Registrant issued SAFEs to accredited investors in an aggregate principal amount of $101.2 million.

• In February 2025, the Registrant issued warrants to purchase up to approximately 0.29% of the Registrant’s capital stock on a fully diluted basis, calculated as of the initial public filing of this registration statement, to accredited investors at an exercise price of $0.01 per share.

• In February 2025, the Registrant issued warrants to purchase up to 1,459,768 shares of its Class A common stock to accredited investors at an exercise price of $0.01 per share.

• In September 2022, the Registrant issued a warrant to purchase up to 1,797,840 shares of its Class A common stock to an accredited investor at an exercise price of $0.01 per share. In November 202